Navigation Links
Cepheid Reports 2012 Second Quarter Results

SUNNYVALE, Calif., July 19, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenues for the second quarter of 2012 of $81.0 million, representing growth of 21% from $67.0 million for the second quarter of 2011.  Net income was $1.1 million, or $0.02 per share, which compares to net income of $1.8 million, or $0.03 per share, in the second quarter of 2011.

Excluding employee stock-based compensation and amortization of purchased intangible assets, non-GAAP net income for the second quarter was $7.9 million, or $0.11 per share.  This compares to non-GAAP net income of $7.2 million, or $0.11 per share, in the second quarter of 2011.

"Growth in our installed base was strong during the second quarter, with a total of 271 GeneXpert system placements.  With a cumulative total of 3,350 placements globally, it is clear that benefits of our innovative system and our growing menu of Xpert tests continues to drive broad market adoption of our GeneXpert system," said John Bishop, Cepheid's Chief Executive Officer.
"We continued to execute well on test menu expansion during the quarter.  Our CT/NG test is now under FDA review in the United States, and we have been very encouraged by early customer feedback following the product's release in Europe."

"Looking forward, we continue to expect sales of our Xpert MTB/RIF test to grow to volumes in the millions in the next several years.  However, we do expect that certain features of the HBDC program could slow our progress on overall profitability goals in the immediate-term," continued Bishop.  "Coupled with a number of macro factors, namely less favorable currency rates and potentially lengthening capital sales cycles as we approach elections here in the United States, we are taking a more cautious view for the remainder of the year."

Operational Overview

  • Total product sales of $78.5 million in the second quarter of 2012 compared to $63.6 million in the second quarter of 2011.  By business, product sales were, in millions:
  • Three Months Ended June 30,20122011ChangeClinical Systems

    3.25%Clinical Reagents

    55.844.127%Total Clinical 69.757.322%Non-Clinical

    8.86.340%Total Product Sales$

  • By geography, product sales were, in millions:
  • Three Months Ended June 30,20122011ChangeNorth AmericaClinical


    6.95.623%Total North America54.447.714%InternationalClinical


    1.90.7171%Total International24.115.952%Total Product Sales$

  • During the quarter, Cepheid installed a total of 133 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 138 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 3,350 GeneXpert systems have been placed worldwide as of June 30, 2012.
  • GAAP gross margin on product sales was 55% and non-GAAP gross margin on product sales was 57%, which compares to 54% and 55%, respectively, in the second quarter of 2011. 
  • Cash and cash equivalents were $97.3 million as of June 30, 2012.
  • DSO was 41 days.
  • Business OutlookFor the fiscal year ending December 31, 2012, the Company expects:

  • Total revenue to be in the range of $333 to $347 million;
  • Net income per share in the range of $0.00 to $0.04; and
  • Non-GAAP net income per share in the range of $0.38 to $0.42. 
  • Expected non-GAAP net income per share excludes the effect of approximately $26 million related to stock-based compensation expense, approximately $2.8 million related to the amortization of acquired intangibles, and a $1.8 million tax benefit related to an intercompany intellectual property transaction.  The fully diluted share count for the year is expected to be between 70 and 71 million.

    The following table reconciles net income per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2012Low HighNet Income Per Share$
    .04Stock Compensation Expense0.370.37Tax Benefit Related to Intercompany IP Transaction(0.03)(0.03)Amortization of Purchased Intangible Assets0.040.04Non-GAAP Measure of Net Income Per Share$
    .42Accessing Cepheid's Second Quarter Results' Conference CallThe Company will host a management presentation at 2:00 p.m. Pacific Time on Thursday, July 19, 2012 to discuss the results.  To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

    Use of Non-GAAP MeasuresThe Company has supplemented its reported GAAP financial information with non-GAAP measures that do not include stock-based compensation expense, amortization of acquired intangible assets and a tax benefit related to an intercompany intellectual property transaction.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.
    The Company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the Company's cash requirements and additional insight into the underlying operating results and the Company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The Company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with U.S. GAAP and that these measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the Company excludes the following items from one or more of its non-GAAP measures when applicable:

    Employee stock-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The Company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results in the period incurred.  Further, as the Company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Amortization of purchased intangible assets.  The Company incurs amortization of purchased intangible assets in connection with acquisitions.  The Company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the Company's prior acquisitions and have no direct correlation to the operation of the Company's business.

    Tax benefit related to an intercompany intellectual property (IP) transaction.  The Company excluded a tax benefit related to an intercompany IP transaction from its results for non-GAAP net loss for the first quarter ended March 31, 2012 and for the six months ended June 30, 2012.  The Company excluded this item as it believes it is non-recurring in nature, and does not have a direct impact on the operation of the Company's core business. 

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to future volumes of product sales and future revenues, future net income per share and  future non-GAAP net income per share.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended June 30,Six months EndedJune 30, 2012201120122011Revenues:System sales

    $ 14,539$ 14,138$ 27,770$ 26,829Reagent and disposable sales

    63,91549,454125,97794,400Total product sales

    78,45463,592153,747121,229Other revenues

    2,5613,4374,5606,019Total revenues

    81,01567,029158,307127,248Costs and operating expenses:Cost of product sales

    35,07229,25470,68054,564Collaboration profit sharing

    1,6451,0933,3292,185Research and development

    16,11813,91538,22027,489Sales and marketing

    15,10811,87929,62023,326General and administrative

    11,0118,90522,06216,535Total costs and operating expenses

    78,95465,046163,911124,099Income (loss) from operations

    2,0611,983(5,604)3,149Other expense, net

    (572)(400)(334)(599)Income (loss) before income taxes

    1,4891,583(5,938)2,550Benefit from (provision for) income taxes

    (354)2441,547(196)Net income (loss)

    $ 1,135$ 1,827$ (4,391)$ 2,354Basic net income (loss) per share

    $ 0.02$ 0.03$ (0.07)$ 0.04Diluted net income (loss) per share

    $ 0.02$ 0.03$ (0.07)$ 0.04Shares used in computing basic net income (loss) per share

    65,69562,12065,36161,638Shares used in computing diluted net income (loss) per share

    68,86966,39065,36165,727 CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)June 30, 2012December
    31, 2011ASSETSCurrent assets:Cash and cash equivalents

    97,267$  115,008Accounts receivable, net


    70,99762,239Prepaid expenses and other current assets 

    12,7215,245Total current assets

    217,811217,867Property and equipment, net

    45,79535,833Other non-current assets

    834730Intangible assets, net


    26,91118,445Total assets

    310,440$  286,670LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 

    32,167Accrued compensation 

    16,61617,928Accrued royalties 

    7,8788,357Accrued and other liabilities 

    2,3353,086Current portion of deferred revenue

    8,4188,176Current portion of notes payable

    161-Total current liabilities 

    62,08869,714Long-term portion of deferred revenue

    2,2002,003Notes payable, less current portion

    1,623-Other liabilities

    4,2683,120Total liabilities

    70,17974,837Shareholders' equity:Common stock

    345,302324,211Additional paid-in capital 

    104,73293,144Accumulated other comprehensive income

    17333Accumulated deficit 

    (209,946)(205,555)Total shareholders' equity 

    240,261211,833Total liabilities and shareholders' equity 

    310,440$  286,670 CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Six Months Ended June 30,20122011Cash flows from operating activities:Net income (loss)

    $   (4,391)$
    2,354Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization of property and equipment

    6,3085,031Amortization of intangible assets 

    2,6333,452Stock-based compensation related to employees and consulting services rendered

    11,5679,343Changes in operating assets and liabilities:Accounts receivable 


    (5,950)(7,650)Prepaid expenses and other current assets 

    (7,475)(1,440)Other non-current assets

    (105)(74)Accounts payable and other current liabilities 

    (12,233)2,145Accrued compensation 

    (1,312)1,069Deferred revenue 

    43813Net cash provided by (used in) operating activities 

    (9,759)10,716Cash flows from investing activities:Capital expenditures 

    (11,168)(6,974)Payments for technology license

    -(1,000)Cost of acquisitions, net

    (17,462)(296)Net cash used in investing activities 

    (28,630)(8,270)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

    21,09116,962Principal payment of notes payable

    -(757)Net cash provided by financing activities 

    21,09116,205Effect of exchange rate change on cash

    (443)63Net increase (decrease) in cash and cash equivalents 

    (17,741)18,714Cash and cash equivalents at beginning of period 

    115,00879,538Cash and cash equivalents at end of period

    $   97,267$   98,252 CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months EndedJune 30,Six Months EndedJune 30,2012201120122011Cost of product sales$ 35,072$ 29,254$ 70,680$ 54,564  Stock compensation expense(700)(435)(1,335)(934)  Amortization of purchased intangible assets(333)(345)(666)(689)Non-GAAP measure of cost of product sales$ 34,039$ 28,474$ 68,679$ 52,941Gross margin on product sales per GAAP55%54%54%55%Gross margin on product sales per Non-GAAP57%55%55%56%Operating expenses$ 42,237$ 34,699$ 89,902$ 67,350  Stock compensation expense(5,346)(4,508)(10,209)(8,409)  Amortization of purchased intangible assets(381)(107)(697)(215)Non-GAAP measure of operating expenses$ 36,510$ 30,084$ 78,996$ 58,726Income (loss) from operations$   2,061$ 1,983$ (5,604)$  3,149  Stock compensation expense6,0464,94311,5449,343  Amortization of purchased intangible assets7144521,363904Non-GAAP measure of income from operations$  8,821$ 7,378$  7,303$ 13,396Net income (loss)$   1,135$ 1,827$  (4,391)$  2,354  Stock compensation expense6,0464,94311,5449,343  Tax benefit related to intercompany IP transaction--(1,815)-  Amortization of purchased intangible assets7144521,363904Non-GAAP measure of net income$   7,895$ 7,222$  6,701$ 12,601Basic net income (loss) per share$
    .02$  0.03$   (0.07)$
    .04  Stock compensation expense0.  Tax benefit related to intercompany IP transaction--(0.03)-  Amortization of purchased intangible assets0. measure of net income per share$
    .12$ 0.12$
    .20Diluted net income (loss) per share$
    .02$  0.03$   (0.07)$
    .04  Stock compensation expense0.  Tax benefit related to intercompany IP transaction--(0.03)-  Amortization of purchased intangible assets0. measure of net income per share$
    .11$ 0.11$  0.10$   0.19Shares used in computing basic net income (loss) per share65,69562,12065,36161,638Shares used in computing diluted net income (loss) per share68,86966,39065,36165,727  Impact of dilutive securities in periods of GAAP net loss and Non-GAAP net income--3,174-Shares used in computing Non-GAAP diluted net income per share68,86966,39068,53565,727For Media Inquiries:For Investor Inquiries:Jared TiptonJacquie RossCepheid Corporate CommunicationsCepheid Investor RelationsTel: (408) 400 8377Tel: (408) 400

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    2. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    3. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    5. Cepheid to Webcast Upcoming Financial Presentations
    6. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    7. Cepheid Welcomes Senior Vice President of Human Resources
    8. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
    9. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
    10. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
    11. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
    Post Your Comments:
    (Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
    (Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
    (Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
    Breaking Biology Technology:
    (Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
    (Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
    (Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
    Breaking Biology News(10 mins):